Fig. 2: CT2A and EO771 study.

A Timeline of study design. CT2A-Luc tumor implanted and resected 2 weeks later (day 0). Ace-Resi or bolus resiquimod treatment applied immediately following tumor resection. Surviving mice were challenged at 9 weeks and then again at 15 weeks. Mice euthanized at 16 weeks for brain lymphocyte analysis. B Survival of mice after tumor resection and treatment with Ace-Blank (n = 4 mice), soluble resiquimod 100 µg (n = 5 mice), or Ace-Resi 100 µg (n = 19 mice). One independent experiment. P-value, log-rank test. C Representative bioluminescent images of mice after tumor resection. D Survival of mice after the first tumor challenge. Ace-Resi 100 µg (n = 6 mice) with naïve mice (n = 5) as controls. One independent experiment. P-value, log-rank test. E Representative bioluminescent images of mice following the first tumor challenge. F Percent of T cells that are positive for IFNγ. Healthy (no tumor, n = 5 mice) and tumor (n = 5 mice) controls, and n = 6 Ace-Resi 100 µg mice, one independent experiment. Data are presented as mean ± SD. P-value, one-way ANOVA, Tukey’s multiple comparisons test. G CD8⁺ T cells that are positive for both IFNγ and granzyme B. Healthy (no tumor, n = 5 mice) and tumor (n = 5 mice) controls, and n = 6 Ace-Resi 100 µg mice, one independent experiment. Data are presented as mean ± SD. P-value, one-way ANOVA, Tukey’s multiple comparisons test. H IFNγ in the supernatant of effector cells (isolated from n = 3 long-term survivors and pooled together) co-cultured with CT2A-Par cells (‘target cells’) for 24 hours in n = 3 or n = 6 individual wells. One independent experiment. Data are presented as mean ± SD. P-value, one-way ANOVA, Tukey’s multiple comparisons test. I Survival of mice after EO771 tumor resection and treatment with Ace-Blank (n = 5 mice) or Ace-Resi 100 µg (n = 9 mice), one independent experiment. P-value, log-rank test.